CYCN News and Press, Cyclerion Therapeutics Inc. From 01/26/22

CAMBRIDGE, Mass., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that patient dosing has begun in its Phase 2a study in Alzheimer&#x...

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that management will attend the Jefferies London Healthcare Confere...

Cyclerion Therapeutics (NASDAQ:CYCN): Q3 GAAP EPS of -$0.26 beats by $0.09. Revenue of $0.35M (-12.5% Y/Y) misses by $1.15M. 10-Q Press Release For further details see: Cyclerion Therapeutics EPS beats by $0.09, misses on revenue

First patients enrolled in study in Cognitive Impairment Associated with Schizophrenia (CIAS) Patient screening underway in study in Alzheimer’s disease with vascular pathology (ADv) Enrollment ongoing in study in Mitochondrial Encephalomyopathy, Lactic Acidosis, an...

Cyclerion is a spinoff from Ironwood Pharmaceuticals that has had 2 clinical failures but has a unique lead asset in neurodegeneration. Cyclerion has upcoming phase 2 data coming out in H12022 that will be a major inflection point to potentially open up new opportunities for the distr...

5 Trending Penny Stocks to Add to Your Watchlist Right Now After a volatile and exciting week of trading penny stocks, investors show bullish sentiment in the stock market. Last week, we witnessed record highs with the S&P 500 and Bitcoin, both illustrating just how much positivity ...

LumiraDx (NASDAQ:LMDX) +37% after approval for COVID-19 antigen test in India Troika Media (NASDAQ:TRKA) +32%. Puhui Wealth Investment Management (NASDAQ:PHCF) +16%. Valneva  (NASDAQ:VALN) +16%. Xiaobai Maimai (NASDAQ:HX) +11%. Cyclerion Therapeutics (NASDAQ:CYCN) +11%. F-star ...

CAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments that restore cognitive function, today announced a publication demonstrating that administration of a small molecule soluble gua...

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Company management will present at two upcoming investor conf...

CAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced participation in the Annual Biomarkers for Alzheimer’s Dis...